Exogenous IL-1Ra attenuates intestinal mucositis induced by oxaliplatin and 5-fluorouracil through suppression of p53-dependent apoptosis

Anti-Cancer Drugs

Volumn 26, Issue 1, 2015, Pages 35-45

  Wang, Xia ^a   Gao, Jin ^a   Qian, Lan ^a   Gao, Jing ^a   Zhu, Shunying ^a   Wu, Mingyuan ^a   Zhang, Yang ^a   Guan, Wen ^a   Ye, Hao ^a   Yu, Yan ^a   Han, Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

5 fluorouracil; apoptosis; mortality; mucositis; oxaliplatin; p53; recombinant human interleukin 1 receptor antagonist

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; FLUOROURACIL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; OCTREOTIDE; OXALIPLATIN; PLATINUM COMPLEX; PROTEIN P53; RECOMBINANT PROTEIN;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; COLONIC NEOPLASMS; DIARRHEA; DRUG EFFECTS; KNOCKOUT MOUSE; METABOLISM; MUCOSITIS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; COLONIC NEOPLASMS; DIARRHEA; FLUOROURACIL; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MICE, INBRED BALB C; MICE, KNOCKOUT; MUCOSITIS; OCTREOTIDE; ORGANOPLATINUM COMPOUNDS; RECOMBINANT PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84940279453     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000142     Document Type: Article

References (34)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
2. Carrato A. Adjuvant treatment of colorectal cancer. Gastrointest Cancer Res 2008; 2:S42-S46.
3. Cunningham D, Morgan RJ, Mills PR, Nelson LM, Toner PG, Soukop M, et al. Functional and structural changes of the human proximal small intestine after cytotoxic therapy. J Clin Pathol 1985; 38:265-270.
4. Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer 2006; 14:890-900.
5. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109:820-831.
6. Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2010; 2:51-63.
7. Bowen JM, Gibson RJ, Cummins AG, Keefe DM. Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer 2006; 14:713-731.
8. Duncan M, Grant G. Oral and intestinal mucositis - causes and possible treatments. Aliment Pharmacol Ther 2003; 18:853-874.
9. Logan RM, Gibson RJ, Bowen JM, Stringer AM, Sonis ST, Keefe DM. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 2008; 62:33-41.
10. Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 2009; 63:239-251.
11. Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 2008; 7:1139-1145.
12. Kanarek N, Grivennikov SI, Leshets M, Lasry A, Alkalay I, Horwitz E, et al. Critical role for IL-1beta in DNA damage-induced mucositis. Proc Natl Acad Sci USA 2014; 111:E702-E711.
13. Al-Sadi RM, Ma TY. IL-1beta causes an increase in intestinal epithelial tight junction permeability. J Immunol 2007; 178:4641-4649.
14. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16:27-55.
15. Daig R, Rogler G, Aschenbrenner E, Vogl D, Falk W, Gross V, et al. Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6. Gut 2000; 46:350-358.
16. Wu Z, Han X, Qin S, Zheng Q, Wang Z, Xiang D, et al. Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-fluorouracil in a mouse mucositis model. Biomed Pharmacother 2010; 64:589-593.
17. Cominelli F, Nast CC, Duchini A, Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992; 103:65-71.
18. Ferretti M, Casini-Raggi V, Pizarro TT, Eisenberg SP, Nast CC, Cominelli F. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 1994; 94:449-453.
19. Wu ZQ, Han XD, Wang Y, Yuan KL, Jin ZM, Di JZ, et al. Interleukin-1 receptor antagonist reduced apoptosis and attenuated intestinal mucositis in a 5-fluorouracil chemotherapy model in mice. Cancer Chemother Pharmacol 2011; 68:87-96.
20. Xiang D, Guo Y, Zhang J, Gao J, Lu H, Zhu S, et al. Interleukin-1 receptor antagonist attenuates cyclophosphamide-induced mucositis in a murine model. Cancer Chemother Pharmacol 2011; 67:1445-1453.
21. Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 2003; 18:1095-1100.
22. Wang DS, Ueno Y, Oyamada H, Kojima S. Enhancement of the antitumor effect of gamma-ray irradiation in combination with camptothecin against human colorectal adenocarcinoma. Biol Pharm Bull 1996; 19:354-359.
23. Pritchard DM, Potten CS, Hickman JA. The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracilinduced histopathology in murine intestinal epithelia. Cancer Res 1998; 58:5453-5465.
24. Bowen JM, Gibson RJ, Keefe DM, Cummins AG. Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 2005; 37:56-62.
25. Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2008; 12:iii-ix, xi-162.
26. Dipetrillo T, Pricolo V, Lagares-Garcia J, Vrees M, Klipfel A, Cataldo T, et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys 2012; 82:124-129.
27. Haller DG. Safety of oxaliplatin in the treatment of colorectal cancer. Oncology 2000; 14:15-20.
28. Diego Cardani GFD, Luchini Patrizia, Sciarabba Michele, Solimene Umberto, Rumio Cristiano. Oral administration of interleukin-10 and anti-il-1 antibody ameliorates experimental intestinal inflammation. Gastroenterol Res 2013; 6:124-133.
29. Stringer AM, Gibson RJ, Bowen JM, Logan RM, Yeoh AS, Keefe DM. Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol 2007; 5:259-267.
30. Ijiri K, Potten CS. Response of intestinal cells of differing topographical and hierarchical status to ten cytotoxic drugs and five sources of radiation. Br J Cancer 1983; 47:175-185.
31. Ijiri K, Potten CS. Further studies on the response of intestinal crypt cells of different hierarchical status to eighteen different cytotoxic agents. Br J Cancer 1987; 55:113-123.
32. Tassone P, Tagliaferri P, Galea E, Palmieri C, Bonelli P, Martelli ML, et al. Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death. Eur J Cancer 2002; 38:1141-1147.
33. William-Faltaos S, Rouillard D, Lechat P, Bastian G. Cell cycle arrest and apoptosis induced by oxaliplatin (L-OHP) on four human cancer cell lines. Anticancer Res 2006; 26:2093-2099.
34. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-338.